These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. [Measurement of the secretion of growth hormone in patients with thalassemia major]. De Luca G; Maggiolini M; Bria M; Caracciolo M; Lanzino M; Le Pera M; Brancati C; Andò S Minerva Endocrinol; 1993 Sep; 18(3 Suppl 1):62-5. PubMed ID: 7910656 [No Abstract] [Full Text] [Related]
11. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report. Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548 [No Abstract] [Full Text] [Related]
12. [Anomalies of the masticatory apparatus in beta-thalassemia. The present status after transfusion and iron-chelating therapy]. Scutellari PN; Orzincolo C; Andraghetti D; Gamberini MR Radiol Med; 1994 Apr; 87(4):389-96. PubMed ID: 8190919 [TBL] [Abstract][Full Text] [Related]
13. Short stature and body proportion in thalassaemia. Caruso-Nicoletti M; De Sanctis V; Capra M; Cardinale G; Cuccia L; Di Gregorio F; Filosa A; Galati MC; Lauriola A; Malizia R; Mangiagli A; Massolo F; Mastrangelo C; Meo A; Messina MF; Ponzi G; Raiola G; Ruggiero L; Tamborino G; Saviano A J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():811-6. PubMed ID: 10091151 [TBL] [Abstract][Full Text] [Related]
15. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651 [TBL] [Abstract][Full Text] [Related]
16. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. Ehlers KH; Giardina PJ; Lesser ML; Engle MA; Hilgartner MW J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928 [TBL] [Abstract][Full Text] [Related]
17. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency. Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155 [TBL] [Abstract][Full Text] [Related]
19. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Cazzola M; Borgna-Pignatti C; Locatelli F; Ponchio L; Beguin Y; De Stefano P Transfusion; 1997 Feb; 37(2):135-40. PubMed ID: 9051086 [TBL] [Abstract][Full Text] [Related]
20. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience. Calleja EM; Shen JY; Lesser M; Grady RW; New MI; Giardina PJ Ann N Y Acad Sci; 1998 Jun; 850():469-70. PubMed ID: 9668587 [No Abstract] [Full Text] [Related] [Next] [New Search]